Gyrodyne , LLC (NASDAQ:GYRO – Get Free Report) was the target of a significant decline in short interest in the month of April. As of April 30th, there was short interest totaling 53 shares, a decline of 94.6% from the April 15th total of 989 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 947 shares, the short-interest ratio is currently 0.1 days.
Gyrodyne Price Performance
GYRO stock traded down $0.12 during midday trading on Monday, hitting $7.36. The stock had a trading volume of 451 shares, compared to its average volume of 1,096. Gyrodyne has a 1-year low of $6.70 and a 1-year high of $12.00. The business has a fifty day moving average price of $7.96 and a two-hundred day moving average price of $8.80.
Institutional Investors Weigh In On Gyrodyne
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisory Services Network LLC bought a new stake in Gyrodyne in the third quarter valued at $77,000. Susquehanna International Group LLP bought a new stake in Gyrodyne in the third quarter valued at $142,000. Teton Advisors LLC bought a new stake in Gyrodyne in the third quarter valued at $177,000. Finally, Bulldog Investors LLP bought a new stake in Gyrodyne in the third quarter valued at $601,000. 71.36% of the stock is owned by institutional investors.
About Gyrodyne
Gyrodyne Company of America, Inc is a New York–based real estate investment and development firm specializing in medical office buildings and professional facilities. Listed on the NASDAQ under the ticker GYRO, the company’s principal business activity is the ownership, leasing and management of commercial properties tailored to healthcare and life sciences tenants. By focusing on outpatient diagnostic and treatment centers, clinical laboratories and related professional suites, Gyrodyne generates steady rental income and seeks to provide purpose-built environments that meet the specific needs of medical practitioners and research organizations.
The company’s core property portfolio is anchored by an approximately 87-acre campus situated in Stony Brook, Long Island.
Read More
- Five stocks we like better than Gyrodyne
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Gyrodyne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyrodyne and related companies with MarketBeat.com's FREE daily email newsletter.
